Cardiology News

Get updates on cardiology with press releases highlighting research, treatments, and innovations advancing heart health and cardiovascular medicine. Explore developments influencing cardiology and opportunities in medical advancements and heart disease prevention.

Jun 1, 2026 at 9:00 AM

Sermo Barometer Finds Nearly Half of Physicians Report Patients are Using Non-FDA Regulated Peptides

NEW YORK--(BUSINESS WIRE)--Sermo Barometer Finds Nearly Half of Physicians Report Patients are Using Non-FDA Regulated Peptides...
Jun 1, 2026 at 9:00 AM

Corsair Pharma Announces Positive Phase 1 Results for the TRX-248 Transdermal System in Pulmonary Arterial Hypertension

NEWARK, Calif.--(BUSINESS WIRE)--Corsair Pharma Announces Positive Phase 1 Results for the TRX-248 Transdermal System in Pulmonary Arterial Hypertension...
Jun 1, 2026 at 7:45 AM

Teleflex Incorporated Announces Private Offering of $500 Million of Senior Notes Due 2032

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) (“Teleflex”) announced today the commencement of a private offering of $500.0 million aggregate principal amount of senior notes due 2032 (the “Notes”), subject to market and other conditions. The interest rate and other terms of the Notes will be determined at pricing. The Notes will be guaranteed by each of Teleflex’s existing and future wholly-owned domestic subsidiaries that is a guarantor or other obligor under its credit agree...
Jun 1, 2026 at 6:59 AM
May 31, 2026 at 8:00 AM

Kelonia Therapeutics Presents Updated First-in-Human Data from Phase 1 inMMyCAR Study of KLN-1010 in vivo BCMA CAR-T Therapy at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

BOSTON--(BUSINESS WIRE)--Kelonia Therapeutics, Inc., a clinical-stage biotechnology company pioneering in vivo gene delivery, today shared positive updated results from inMMyCAR, the ongoing first-in-human Phase 1 study of KLN-1010 in patients with relapsed and refractory multiple myeloma (RRMM), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. Fourteen additional patients have been dosed since first clinical data were reported at the American Societ...
May 30, 2026 at 2:30 PM

Salubris Biotherapeutics Announces Updated Phase 1/2 Data for JK06, a 5T4-Targeted Antibody Drug Conjugate, at the 2026 American Society of Clinical Oncology Annual Meeting

GAITHERSBURG, Md.--(BUSINESS WIRE)--Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced updated data from the Phase 1/2 study of JK06, a 5T4-targeted antibody drug conjugate (ADC), in patients with unresectable locally advanced or metastatic solid tumors, including non-small cell lung cancer (NSCLC) and breast cancer. The data are being presented at the 2026 American Soc...
May 30, 2026 at 8:00 AM
May 29, 2026 at 12:31 PM

ChristianaCare to Open Aston Campus Neighborhood Hospital in Early June, Bringing 24/7 Emergency Care to Delaware County, PA

WILMINGTON, Del.--(BUSINESS WIRE)--Residents of Delaware County will soon have a new option for around-the-clock emergency and inpatient care closer to home. In early June, ChristianaCare will open ChristianaCare Hospital, Aston, a neighborhood hospital designed to expand access to care in a growing region with increasing health care needs. Download photos. The hospital is expected to care for approximately 15,000 patients each year, or about 40 per day, and will provide 24/7 emergency care, in...
May 29, 2026 at 10:30 AM

HeartFocus Launches HeartFocus Link, Bringing AI-Guided Cardiac Ultrasound Education and Guidance to Any Cart-Based System

BORDEAUX, France--(BUSINESS WIRE)--HeartFocus, AI-enabled cardiac imaging software developed by data-driven medtech company DESKi, has announced its expansion to any cart-based system with the launch of HeartFocus Link. Available now for medical schools, residency, and ultrasound training programs, HeartFocus Link addresses one of the most persistent barriers in cardiac ultrasound education and adoption: the challenge of helping healthcare professionals build confidence and competency using the...
May 29, 2026 at 6:00 AM

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further suppo...
Turn Your News Into Headlines
Submit Your Release

Get Story Ideas Delivered to Your Inbox

Sign Up